This study examined the effect of efpeglenatide in patients with T2DM and cardiovascular or kidney disorders, focusing on MACEs, extended MACEs, composite renal endpoints, and MACEs or death. This study also assessed the combined effects of SGLT2 inhibitors and efpeglenatide on clinical outcomes, and whether the efficacy and safety of efpeglenatide were influenced by concurrent SGLT2 inhibitor use. This evidence concerns the gene SLC5A2 and kidney disorder.